Roxee Medication Guide

Marbofloxacin

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Chewable tablet Multiple FDA labelers Official label facts Owner quick guide first

Start Symptom Intake Talk to a Vet / Find a Vet Near You

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts

Reference refreshed

Jun 22, 2026, 10:41 a.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications

FDA application data refreshed

Jun 22, 2026, 10:41 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports

Safety data refreshed

Jun 21, 2026, 5:14 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details

Reference facts: Source Roxee | Refreshed Jun 22, 2026, 10:41 AM UTC
The reference fact projection used for browse cards and quick facts.
Animal Drugs @ FDA: Source FDA | Refreshed Jun 22, 2026, 10:40 AM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Jun 22, 2026, 10:41 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC

Image coming soon

Marbofloxacin

Drug type: Generic ingredient • Branded profile • FDA branded products available

Both Chewable tablet Rx required 100% reference complete

Species: Both

Manufacturer: Multiple FDA labelers

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Marbofloxacin

For the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin. For the treatment of infections in cats associated with bacteria susceptible to marbofloxacin. For the treatment of otitis externa associated with susceptible strains of yeast ( Malassezia pachydermatis ) and bacteria ( Staphylococcus pseudintermedius ) in dogs. Species commonly shown: Both, Dog, Cat.

Generic name

Marbofloxacin

Brand names

Zeniquin®, Marboquin™, Marbofloxacin Chewable Tablets, Marbofloxacin

Manufacturer

Multiple FDA labelers

Species

Both, Dog, Cat

Dosage forms

Chewable tablet, Tablet, Chewable Tablets

Prescription

Prescription required

Completeness

100%

Validation

Complete

Brand names

Zeniquin® Marboquin™ Marbofloxacin Chewable Tablets Marbofloxacin Cronoquin™ Tablets Marboquin DELAQUIN FluoroFlox Zeniquin X

Dosage forms

Chewable tablet Tablet Chewable Tablets

Indications / Uses

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.

Side Effects

Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Lack of efficacy - NOS, Anorexia, Other abnormal test result NOS, Death by euthanasia.

FAQ

Both, Dog, Cat

Yes. Roxee shows this as prescription-only.

Chewable tablet, Tablet, Chewable Tablets

Related Conditions

Urinary tract infection (cystitis) Otitis Externa (Ear Infection)

Source Transparency

Verified source: https://www.roxee.ai/meds/
Verified source: https://animaldrugsatfda.fda.gov
Verified source: https://animaldrugsatfda.fda.gov/adafda/views/#/search
Verified source: https://api.fda.gov/animalandveterinary/event.json
Verified source: https://www.roxee.ai/conditions/
Verified source: https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/668
Last refreshed: Jun 22, 2026, 10:41 a.m.
Last verified: Feb 12, 2026, 10:44 p.m.
Validation status: Complete

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

Fever (1 reports)
Epidermal collarette (1 reports)
Elevated total bilirubin (1 reports)

When to call the vet:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.
Facial swelling or hives.
Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

Is this medicine the right fit for my pet’s current symptoms?
Which warning signs mean I should call back right away?
How should I handle missed doses or refusal to take the medicine?

Next actions

Talk to a Vet / Find a Vet Near You Save to pet meds Share page Review report evidence

Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Marbofloxacin; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2025-US-048791

Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 27 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2025-US-048791

Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2025-US-048791

Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Fever (1 reports), Epidermal collarette (1 reports), Elevated total bilirubin (1 reports), Elevated symmetrical dimethylarginine (1 reports), Elevated serum alkaline phosphatase (1 reports)

Body systems represented Signal grouping

Digestive (2), Behavior (2), Other (28)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Dog (17 reports), Cat (15 reports)

Breed metadata in reports Metadata only

['Terrier (unspecified)', 'Dog (unknown)'] (2), Boxer (German Boxer) (1), ['Retriever - Labrador', 'Dog (unknown)'] (1), ['Hound (unspecified)', 'Dog (unknown)'] (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Marbofloxacin fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

Fever, Epidermal collarette, Elevated total bilirubin

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Marbofloxacin brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.

Vet source depth

openFDA case USA-USFDACVM-2025-US-048791 · adverse_reaction · adverse reactions
Contraindication source · fda_animal_drugs · warnings contraindications
FDA application profile · official_label · quick facts
FDA application profile · official_label · quick facts
Medication usage source · fda_animal_drugs · quick facts
FOI · document · documents
SPL · document · documents
FOI · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: February 12, 2026, 10:44 PM UTC

Sources:

FDA application profile · official_label
FDA application profile · official_label
Medication usage source · fda_animal_drugs
Marbofloxacin Chewable Tablets · official_label
openFDA case USA-USFDACVM-2025-US-048791 · adverse_reaction

Safety & side effects

Side effects to monitor:

Fever
Epidermal collarette
Elevated total bilirubin

Most reported reactions:

Fever (1 reports)
Epidermal collarette (1 reports)
Elevated total bilirubin (1 reports)

Explore reported case details

Emergency warning signs:

Repeated vomiting or diarrhea.
Severe lethargy (hard to wake, very low energy).
Collapse or fainting.
Trouble breathing.

Talk to a Vet / Find a Vet Near You Start Symptom Intake

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species

Cat, Dog

Indication / use

For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

Form / route / dose

Form: Chewable Tablets, Tablet
Route: Oral
Confirm product label and patient-specific plan.

Warnings

High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-l…

Adverse-event caveat

openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Source docs

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both

Manufacturer: Multiple FDA labelers

Form: Chewable Tablets, Tablet

Identifiers:

ANADA: 200586 ANADA: 200733 ANADA: 200736 ANADA: 200761 NADA: 141151 NADA: 141598 NDC Package: 11695-7010-1 NDC Package: 11695-7010-2 NDC Package: 11695-7011-1 NDC Package: 11695-7011-2 NDC Package: 11695-7012-1 NDC Package: 11695-7013-1 NDC Package: 13612-0033-0 NDC Package: 13612-0033-1 NDC Package: 17033-013-10 NDC Package: 17033-013-25 NDC Package: 17033-014-10 NDC Package: 17033-014-25 NDC Package: 17033-015-50 NDC Package: 17033-016-50

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200761 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov/adafda/views/#/home/previewsearch/200736 · official_label · FDA application profile
https://animaldrugsatfda.fda.gov · fda_animal_drugs · Medication usage source

Warnings / Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.

High: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.

Source metadata:

https://animaldrugsatfda.fda.gov · fda_animal_drugs · Contraindication source

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters

openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Stored reports

Matching reports

Active filters

Selected filters

Reaction: Skin ulcer Clear Body system: Effectiveness Clear

Species

Breed

Size / weight

Age

Sex

Seriousness

Outcome

Reaction

Body system

Region

Received after

Received before

Reset

Drill into common report signals

Skin ulcer (4) Behavioural disorder NOS (2) Death (2) Dermal thickening (2) Other (7) Behavior (3) Effectiveness (3) Digestive (2)

Showing up to 50 matching reports.

USA-USFDACVM-2025-US-074110

Received 2025-12-15 · MSK · MSK

Serious

Species: Dog
Breed: ['Retriever - Labrador', 'Dog (unknown)']
Size / weight: 50-99 lb (26.76 Kilogram)
Age: 8+ years (14 Year)
Sex: Female Unknown
Region: USA
Reactions: Skin ulcerBacterial skin infection NOSLack of efficacy (bacteria) - NOS
Body systems: OtherEffectiveness
Outcomes: Ongoing

USA-USFDACVM-2025-US-074245

Received 2025-12-10 · MSK · MSK

Serious

Species: Dog
Breed: ['Hound (unspecified)', 'Dog (unknown)']
Size / weight: 50-99 lb (35.83 Kilogram)
Age: 8+ years (14.5 Year)
Sex: Male Neutered
Region: USA
Reactions: Aspiration pneumoniaLack of efficacy - NOSMedication error NOSAnaemia NOSMass NOSSkin ulcerUrine leakageLimb weaknessProprioception deficitWalking difficultyBarkingAnxietyUrinary tract infectionDiarrhoeaCoughPain NOS
Body systems: OtherEffectivenessBehaviorDigestive
Outcomes: Ongoing

Tap or hover a reaction to see what it means in plain language.

Tracked signals

Reported cases

Serious reports

Species represented

Grouped by Body System

Digestive (2) · Diarrhea, Bloody diarrhoea Behavior (2) · Behavioral disorder (unspecified), Anxiety Other (28) · Glucosuria, Fever, Epidermal collarette

Most Reported Reactions

Body system	Cases	Species	Serious cases
Other	1	Cat	1
Other	1	Dog	1
Other	1	Cat	1
Other	1	Cat	1
Other	1	Cat	1
Other	1	Dog	1
Other	1	Cat	1
Other	1	Cat	1

Species coverage: Dog (17) Cat (15)

View detailed reaction table

Body system	Species	Seriousness	Frequency	Reports
Other	Cat	Non-serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Non-serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Non-serious	-	1
Other	Cat	Non-serious	-	1
Other	Cat	Serious	-	1
Other	Cat	Serious	-	1
Other	Dog	Serious	-	1
Digestive	Cat	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Non-serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1
Digestive	Dog	Serious	-	1
Behavior	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Behavior	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Dog	Serious	-	1
Other	Cat	Serious	-	1

Source metadata:

https://api.fda.gov/animalandveterinary/event.json · adverse_reaction · openFDA case USA-USFDACVM-2025-US-048791

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

Cronoquin™ Tablets SPL · SPL Marbofloxacin SPL · SPL Marbofloxacin Chewable Tablets SPL · SPL

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

No owner handouts linked yet.

Official label / PI

No official label or package insert links yet.

SPL

FOI

Cronoquin™ Tablets

SPL · SPL

Open original

FDA Structured Product Label

Cronoquin™ Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Cronus Pharma Specialities India Private Ltd.
ANADA: 200-761
Status: RX
Form: Tablet
Route: Oral

Composition / specifications

25 mg, 50 mg, 100 mg, or 200 mg marbofloxacin per tablet

Dogs and cats

Indication

For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

Dosage

1.25 mg per pound (/lb) of body weight once daily, but may be increased to 2.5 mg/lb of body weight once daily.

Marbofloxacin

SPL · SPL

Open original

FDA Structured Product Label

Marbofloxacin

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: ZYVET AH, Inc.
ANADA: 200-736
Status: RX
Form: Tablet
Route: Oral
Species: Dog • Cat

Composition / specifications

25 mg, 50 mg, 100 mg, or 200 mg marbofloxacin per tablet

Dogs and cats

Indication

For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

Dosage

The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb. For the treatment of skin and soft tissue infections, Marbofloxacin tablets should be given for 2-3 days beyond the cessation of clinical signs for a maximum of 30 days. For the treatment of urinary tract infections, Marbofloxacin tablets should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.

Marbofloxacin Chewable Tablets

SPL · SPL

Open original

FDA Structured Product Label

Marbofloxacin Chewable Tablets

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Felix Pharmaceuticals Pvt. Ltd.
ANADA: 200-733
Status: RX
Form: Chewable Tablets
Route: Oral
Species: Dog • Cat

Composition / specifications

25 mg, 50 mg, 100 mg, or 200 mg marbofloxacin per tablet

Dogs and cats

Indication

For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

Dosage

The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb. For the treatment of skin and soft tissue infections, Marbofloxacin Chewable Tablets should be given for 2-3 days beyond the cessation of clinical signs for a maximum of 30 days. For the treatment of urinary tract infections, Marbofloxacin Chewable Tablets should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.

Marboquin™

SPL · SPL

Open original

FDA Structured Product Label

Marboquin™

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Dechra Veterinary Products LLC
ANADA: 200-586
Status: RX
Form: Tablet
Route: Oral
Species: Dog • Cat

Composition / specifications

25 mg, 50 mg, 100 mg, and 200 mg

Dogs and cats

Indication

For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

Dosage

The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb.

For the treatment of skin and soft tissue infections, Marboquin™ tablets should be given for 2-3 days beyond the cessation of clinical signs for a maximum of 30 days.

For the treatment of urinary tract infections, Marboquin™ tablets should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.

Zeniquin®

SPL · SPL

Open original

FDA Structured Product Label

Zeniquin®

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor: Zoetis Inc.
NADA: 141-151
Status: RX
Form: Tablet
Route: Oral
Species: Dog • Cat

Composition / specifications

Each tablet contains either 25, 50, 100, or 200 milligrams of marbofloxacin.

Dogs

Indication

For the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin.

Dosage

1.25 milligrams per pound of body weight once daily, but may be increased to 2.5 milligrams per pound of body weight once daily.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.

Cats

FOI · FOI summary

Open original

Source metadata:

https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/17971 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/18330/Cronoquin%E2%84%A2%20Tablets · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/13375 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/13532/Marbofloxacin · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/13365 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/13525/Marbofloxacin%20Chewable%20Tablets · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/8507 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/8509/Marboquin%E2%84%A2 · document · SPL
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/668 · document · FOI
https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFoi/667 · document · FOI

Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness

Reference facts: Source Roxee | Refreshed Jun 22, 2026, 10:41 AM UTC
The reference fact projection used for browse cards and quick facts.
Animal Drugs @ FDA: Source FDA | Refreshed Jun 22, 2026, 10:40 AM UTC
Applications/products are imported from FDA export data.
Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
Label highlights/doc links are fetched from FDA preview endpoints.
Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Jun 22, 2026, 10:41 AM UTC
Package/product NDCs from FDA’s electronic listing directory (XLS).
openFDA reaction terms: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
openFDA case summaries: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC

Official (FDA)

Identity: Generic ingredient • FDA branded products available

Official FDA brands: DELAQUIN FluoroFlox MARBOFLOXACIN Marbofloxacin Marboquin X Zeniquin

Manufacturer mapping: Multiple FDA labelers

Case-reported brands (openFDA): MSK

Catalog species: Both • FDA-labeled species: Cat, Dog

Rx/OTC: RX

Form/route: Chewable Tablets, Tablet • Oral

Applications: ANADA 200-761 • ANADA 200-736 • ANADA 200-733 • ANADA 200-586 • NADA 141-151

NDC: Packages 11695-7010-1 11695-7010-2 11695-7011-1 11695-7011-2 11695-7012-1 11695-7013-1 • Products 11695 13612 17033 46066 48087 51927

Documents: 6 (FOI: 6) • SPL: 5 • Label highlights • Official documents

Safety (openFDA)

Top reactions: Dog 35 • Cat 3 • View

Case summaries: 7 (showing 7) • View

openFDA reports are unverified and do not prove causation.

Explore

Related conditions: Urinary tract infection (cystitis) Otitis Externa (Ear Infection)

Linked using: Fda_Label (0.95), Usage_Inferred (0.78)

Diagnosis Codes

ICD10_CM: H60.90

Otitis externa, unspecified ear

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals. (Contraindication, High)

Top reaction signals

Fever (1) Epidermal collarette (1) Elevated total bilirubin (1) Elevated symmetrical dimethylarginine (1) Elevated serum alkaline phosphatase (1) Elevated lipase (1) Elevated creatinine (1) Elevated aspartate aminotransferase (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers

Package NDC	Product NDC	Status
11695-7010-1	11695	-
11695-7010-2	11695	-
11695-7011-1	11695	-
11695-7011-2	11695	-
11695-7012-1	11695	-
11695-7013-1	11695	-
13612-0033-0	13612	-
13612-0033-1	13612	-
17033-013-10	17033	-
17033-013-25	17033	-
17033-014-10	17033	-
17033-014-25	17033	-
17033-015-50	17033	-
17033-016-50	17033	-
46066-171-32	46066	-
46066-171-33	46066	-
46066-173-32	46066	-
46066-173-33	46066	-
46066-175-31	46066	-
46066-176-31	46066	-

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Marbofloxacin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Marbofloxacin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Marbofloxacin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Marbofloxacin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
MARBOFLOXACIN SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Marbofloxacin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Zeniquin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
DELAQUIN SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
FluoroFlox SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Marboquin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Marbofloxacin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Marbofloxacin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Marbofloxacin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
X SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
MARBOFLOXACIN SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
MARBOFLOXACIN SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
Marbofloxacin SPL • Structured Product Label • Official
FDA Structured Product Label from the electronic animal drug product listing directory.
FOI Summary oA 200-761 Approved January 29, 2026.pdf • FOI summary • Official • Feb. 2, 2026
FDA FOI summary for application 200761
FOI Summary oN 141-598 Approved April 10 2025_ceg_ef.pdf • FOI summary • Official • June 3, 2025
FDA FOI summary for application 141598
FOI Summary oA 200-736 Approved January 13, 2023.pdf • FOI summary • Official • Feb. 1, 2023
FDA FOI summary for application 200736
FOI Summary oA 200-733 Approved January 12, 2023.pdf • FOI summary • Official • Feb. 1, 2023
FDA FOI summary for application 200733
FOI Summary oA 200-586 Approved March 23, 2020.pdf • FOI summary • Official • April 1, 2020
FDA FOI summary for application 200586
ucm117196.pdf • FOI summary • Official • Feb. 12, 2019
FDA FOI summary for application 141151
ucm117199.pdf • FOI summary • Official • Feb. 12, 2019
FDA FOI summary for application 141151

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 143 Clinical 1 Manufacturer 0 Marketing 0

Current Field Facts

side_effects: Top reported reactions (openFDA): Vomiting, Lethargy (see also Central nervous system depression in 'Neurological'), Lack of efficacy - NOS, Anorexia, Other ab… (Clinical, 2026-04-11)
contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing … (Official, 2026-04-12)
contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing … (Official, 2026-04-11)
contraindications: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing … (Official, 2026-02-12)
dosage_forms: Chewable tablet (Official, 2026-06-22)
dosage_forms: Chewable tablet (Official, 2026-06-22)
dosage_forms: Chewable tablet (Official, 2026-06-21)
dosage_forms: Chewable tablet (Official, 2026-06-20)
dosage_forms: Chewable tablet (Official, 2026-06-13)
dosage_forms: Chewable tablet (Official, 2026-06-12)
dosage_forms: Chewable tablet (Official, 2026-06-12)
dosage_forms: Chewable tablet (Official, 2026-06-11)
dosage_forms: Chewable tablet (Official, 2026-06-11)
dosage_forms: Chewable tablet (Official, 2026-06-10)
dosage_forms: Chewable tablet (Official, 2026-06-09)
dosage_forms: Chewable tablet (Official, 2026-06-08)
dosage_forms: Chewable tablet (Official, 2026-06-07)
dosage_forms: Chewable tablet (Official, 2026-06-06)
dosage_forms: Chewable tablet (Official, 2026-06-05)
dosage_forms: Chewable tablet (Official, 2026-06-04)

Recent Revisions

side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product	Sponsor	Application	Status	Published
Cronoquin™ Tablets RX Marbofloxacin Tablet • Oral Label highlights Official documents	Cronus Pharma Specialities India Private Ltd.	ANADA 200-761	Approved	Feb 2, 2026
Marbofloxacin RX Marbofloxacin Tablet • Oral Label highlights Official documents	ZYVET AH, Inc.	ANADA 200-736	Approved	Feb 1, 2023
Marbofloxacin Chewable Tablets RX Marbofloxacin Chewable Tablets • Oral Label highlights Official documents	Felix Pharmaceuticals Pvt. Ltd.	ANADA 200-733	Approved	Feb 1, 2023
Marboquin™ RX Marbofloxacin Tablet • Oral Label highlights Official documents	Dechra Veterinary Products LLC	ANADA 200-586	Approved	Apr 1, 2020
Zeniquin® RX Marbofloxacin Tablet • Oral Label highlights Official documents	Zoetis Inc.	NADA 141-151	Approved	Feb 12, 2019

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Composition / specifications

25 mg, 50 mg, 100 mg, or 200 mg marbofloxacin per tablet

Dogs and cats

Indication

For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

Dosage

1.25 mg per pound (/lb) of body weight once daily, but may be increased to 2.5 mg/lb of body weight once daily.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Cat

Composition / specifications

25 mg, 50 mg, 100 mg, or 200 mg marbofloxacin per tablet

Dogs and cats

Indication

For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

Dosage

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Cat

Composition / specifications

25 mg, 50 mg, 100 mg, or 200 mg marbofloxacin per tablet

Dogs and cats

Indication

For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

Dosage

The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb. For the treatment of skin and soft tissue infections, Marbofloxacin Chewable Tablets should be given for 2-3 days beyond the cessation of clinical signs for a maximum of 30 days. For the treatment of urinary tract infections, Marbofloxacin Chewable Tablets should be administered for at least 10 days. If no improvement is noted within 5 days, the diagnosis should be re-evaluated and a different course of therapy considered.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Cat

Composition / specifications

25 mg, 50 mg, 100 mg, and 200 mg

Dogs and cats

Indication

For the treatment of infections in dogs and cats associated with bacteria susceptible to marbofloxacin.

Dosage

The recommended dosage for oral administration to dogs and cats is 1.25 mg marbofloxacin per lb of body weight once daily, but the dosage may be safely increased to 2.5 mg/lb.

For the treatment of skin and soft tissue infections, Marboquin™ tablets should be given for 2-3 days beyond the cessation of clinical signs for a maximum of 30 days.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog • Cat

Composition / specifications

Each tablet contains either 25, 50, 100, or 200 milligrams of marbofloxacin.

Dogs

Indication

For the treatment of infections in dogs associated with bacteria susceptible to marbofloxacin.

Dosage

1.25 milligrams per pound of body weight once daily, but may be increased to 2.5 milligrams per pound of body weight once daily.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.

Cats

Indication

For the treatment of infections in cats associated with bacteria susceptible to marbofloxacin.

Dosage

1.25 milligrams per pound of body weight once daily, but may be increased to 2.5 milligrams per pound of body weight once daily.

Limitations

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.

FDA page: Open in Animal Drugs @ FDA

Usage

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Federal law restricts this drug to use by or on the order of a licensed veterinarian. Federal law prohibits the extra-label use of this drug in food-producing animals.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive

Diarrhea (1) • Cat Bloody diarrhoea (1) • Dog

Showing top 5 for Digestive.

Behavior

Behavioral disorder (1) • Dog Anxiety (1) • Dog

Showing top 5 for Behavior.

Other

Glucosuria (1) • Cat Fever (1) • Cat Epidermal collarette (1) • Dog Elevated total bilirubin (1) • Cat Elevated symmetrical dimethylarginine (1) • Cat

Show more (23)

Elevated serum alkaline phosphatase (1) • Cat Elevated lipase (1) • Dog Elevated globulins (1) • Cat Elevated creatinine (1) • Cat Elevated blood urea nitrogen (1) • Cat Elevated betahydroxybutyrate (1) • Cat Elevated aspartate aminotransferase (1) • Cat Elevated alanine aminotransferase (1) • Cat Discomfort NOS (1) • Dog Dermal thickening (1) • Dog Dental disease (1) • Cat Death by euthanasia (1) • Dog Death (1) • Dog Cough (1) • Dog Constipation (1) • Dog Cholangitis (1) • Cat Barking (1) • Dog Bacterial skin infection NOS (1) • Dog Aspiration pneumonia (1) • Dog Anaemia NOS (1) • Dog Abnormal ultrasound finding (1) • Dog Abdominal pain (1) • Dog Abdominal mass (1) • Cat

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Boxer (German Boxer), Female, 8 year, 27.3 kilogram • Drug: MSK, Tablet, Oral, Dose: 100 Milligram per animal, Frequency: 1 per day • Reactions: Bloody diarrhoea, Elevated lipase, Pancreatitis NOS, Haemorrhagic gastroenteritis, Intentional misuse • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-075293
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 8.00 Year
Weight: 27.300 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Tablet
Dose: 100 Milligram per animal
Frequency: 1 per day

Reactions Reported:

Bloody diarrhoea Elevated lipase Pancreatitis NOS Haemorrhagic gastroenteritis Intentional misuse

Outcomes: Ongoing

Dog, ['Retriever - Labrador', 'Dog (unknown)'], Female, 14 year, 26.76 kilogram • Drug: MSK, Tablet, Oral • Reactions: Skin ulcer, Bacterial skin infection NOS, Lack of efficacy (bacteria) - NOS • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-074110
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 14.00 Year
Weight: 26.760 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Tablet

Reactions Reported:

Skin ulcer Bacterial skin infection NOS Lack of efficacy (bacteria) - NOS

Outcomes: Ongoing

Dog, ['Hound (unspecified)', 'Dog (unknown)'], Male, 14.5 year, 35.83 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Aspiration pneumonia, Lack of efficacy - NOS, Medication error NOS, Anaemia NOS, Mass NOS… • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-074245
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 14.50 Year
Weight: 35.830 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown
Form: Unassigned

Reactions Reported:

Aspiration pneumonia Lack of efficacy - NOS Medication error NOS Anaemia NOS Mass NOS Skin ulcer Urine leakage Limb weakness Proprioception deficit Walking difficulty Barking Anxiety Urinary tract infection Diarrhea Cough Pain NOS

Outcomes: Ongoing

Dog, ['Terrier (unspecified)', 'Dog (unknown)'], Male, 9 year, 18.14 kilogram • Drug: MSK, Unknown • Reactions: Behavioral disorder (unspecified), Epidermal collarette, Hepatic toxicosis, Dermal thickening, Pyoderma… • Outcome: Died

Report ID: USA-USFDACVM-2025-US-074320
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 9.00 Year
Weight: 18.140 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown

Reactions Reported:

Behavioral disorder (unspecified) Epidermal collarette Hepatic toxicosis Dermal thickening Pyoderma Joint swelling Local swelling Skin ulcer Tiredness (lethargy) Itching Hair loss NOS Death Inappetence

Outcomes: Died

Report ID: USA-USFDACVM-2025-US-068424
Serious AE: Yes
Treated For AE: Yes
Sex: Male
Age: 9.00 Year
Weight: 18.140 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown

Reactions Reported:

Outcomes: Died

Cat, Domestic Shorthair, Female, 11 year, 5.806 kilogram • Drug: MSK, Tablet, Oral, Dose: 1 dose per animal, Frequency: 1 per day • Reactions: Fever, Lack of efficacy - NOS • Outcome: Ongoing

Report ID: USA-USFDACVM-2025-US-065991
Serious AE: Yes
Treated For AE: Yes
Sex: Female
Age: 11.00 Year
Weight: 5.806 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Oral
Form: Tablet
Dose: 1 dose per animal
Frequency: 1 per day

Reactions Reported:

Fever Lack of efficacy - NOS

Outcomes: Ongoing

Cat, Domestic Mediumhair, Female, 11 year, 3.9 kilogram • Drug: MSK, Unknown • Reactions: Elevated betahydroxybutyrate • Outcome: Outcome Unknown

Report ID: USA-USFDACVM-2025-US-063885
Serious AE: No
Treated For AE: No
Sex: Female
Age: 11.00 Year
Weight: 3.900 Kilogram

Case-reported brand: MSK
Case-reported manufacturer: MSK
Route: Unknown

Reactions Reported:

Elevated betahydroxybutyrate

Outcomes: Outcome Unknown

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

No community reviews yet. Be the first to share your experience.

This medication has not been reviewed by a veterinarian yet.

Medical Disclaimer: The medication details provided on Roxee are for informational purposes only and are not a substitute for professional veterinary advice. Always consult your veterinarian about your pet's specific needs.

Marbofloxacin

Data freshness

Marbofloxacin

Medication Snapshot

Marbofloxacin

Indications / Uses

Warnings / Contraindications

Side Effects

FAQ

What species is this commonly shown for?

Does this usually require a prescription?

What dosage forms are listed?

Related Conditions

Source Transparency

Add to My Pet's Medications

Pet Owner Quick Guide

Next actions

Medication Research Insights

What to know

Evidence tension

Reaction signal map

Species and breed lens

What your vet may verify

What to watch next

Evidence

Vet Fast Scan

Quick Facts

Warnings / Contraindications

Adverse Reactions

Reported case explorer

USA-USFDACVM-2025-US-074110

USA-USFDACVM-2025-US-074245

Grouped by Body System

Most Reported Reactions

Source Documents

Owner handouts

Official label / PI

SPL

FOI

Cronoquin™ Tablets

Cronoquin™ Tablets

Dogs and cats

Marbofloxacin

Marbofloxacin

Dogs and cats

Marbofloxacin Chewable Tablets

Marbofloxacin Chewable Tablets

Dogs and cats

Marboquin™

Marboquin™

Dogs and cats

Zeniquin®

Zeniquin®

Dogs

Cats

Marbofloxacin SPL

Marbofloxacin SPL

Marbofloxacin SPL

Marbofloxacin SPL

MARBOFLOXACIN SPL

Marbofloxacin SPL

Zeniquin SPL

DELAQUIN SPL

FluoroFlox SPL

Marboquin SPL

Marbofloxacin SPL

Marbofloxacin SPL

Marbofloxacin SPL

X SPL

MARBOFLOXACIN SPL

MARBOFLOXACIN SPL

Marbofloxacin SPL

FOI Summary oA 200-761 Approved January 29, 2026.pdf

FOI Summary oA 200-736 Approved January 13, 2023.pdf

FOI Summary oA 200-733 Approved January 12, 2023.pdf

FOI Summary oA 200-586 Approved March 23, 2020.pdf

ucm117199.pdf

ucm117196.pdf

FOI Summary oN 141-598 Approved April 10 2025_ceg_ef.pdf

At a Glance